How one startup foretold the neuroscience renaissance after '50 years of shitshow'
In the past couple of years, something curious has happened: Pharma and VC dollars started gushing into neuroscience research.
Biogen’s controversial new Alzheimer’s drug Aduhelm has been approved on the basis of removing amyloid plaque from the brain, but the new neuro-focused pharma and biotechs have much loftier aims. Significantly curbing or even curing the most notorious disorders would prove the Holy Grail for a complex system that has tied the world’s best drug developers in knots for decades.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.